Dyne Therapeutics, Inc.
DYN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$317,418 | -$235,937 | -$168,099 | -$149,291 |
| Dep. & Amort. | -$1,931 | $1,673 | $1,683 | $1,088 |
| Deferred Tax | $0 | $0 | $0 | $2,588 |
| Stock-Based Comp. | $45,864 | $19,972 | $15,178 | $17,542 |
| Change in WC | -$19,491 | $26,307 | -$5,379 | $9,256 |
| Other Non-Cash | $607 | -$173 | $2,972 | -$746 |
| Operating Cash Flow | -$292,369 | -$188,158 | -$153,645 | -$119,563 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$2,376 | -$729 | -$3,067 | -$3,618 |
| Net Acquisitions | $0 | $0 | $34 | $8 |
| Inv. Purchases | -$317,443 | -$44,262 | -$121,176 | -$236,721 |
| Inv. Sales/Matur. | $115,708 | $128,302 | $211,445 | $102,447 |
| Other Inv. Act. | $35 | $0 | -$34 | -$8 |
| Investing Cash Flow | -$204,076 | $83,311 | $87,202 | -$137,892 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $773,051 | $52,369 | $36,861 | $157,237 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $36,844 | $1,953 | $529 | $584 |
| Financing Cash Flow | $809,895 | $54,322 | $37,390 | $157,821 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $313,450 | -$50,525 | -$29,053 | -$99,634 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $123,941 | $174,466 | $203,519 | $303,153 |
| End Cash | $437,391 | $123,941 | $174,466 | $203,519 |
| Free Cash Flow | -$294,745 | -$188,887 | -$156,712 | -$123,181 |